ArticlePLoS neglected tropical diseases2010
Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.
Article in PLoS neglected tropical diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul.PLoS neglected tropical diseases · 2014Trial
- Spatial mapping of Ethiopian cutaneous leishmaniasis lesions reveals distinct tissue level immune programs.Frontiers in immunology · 2026Article
- Article
- Leishmania amazonensis impairs phagosome acidification in B-1 phagocytes as an unrecognized parasite infection and proliferation mechanism.Scientific reports · 2025Article
- Ambiguities in cutaneous leishmaniasis classification and the need for consensus: Experience from Ethiopia.PLoS neglected tropical diseases · 2025Article
- Coordination of Neutrophil and Apoptosis-Inducing Ligand in Inflammatory Diseases.Journal of inflammation research · 2025Review
- Role of neutrophils in the pathogenesis of Post Kala-azar Dermal Leishmaniasis (PKDL).PLoS neglected tropical diseases · 2024Article
- Involvement of Inflammatory Cytokines, Renal NaPi-IIa Cotransporter, and TRAIL Induced-Apoptosis in Experimental Malaria-Associated Acute Kidney Injury.Pathogens (Basel, Switzerland) · 2024Article
- Early Leukocyte Responses inFrontiers in cellular and infection microbiology · 2021Article
- The Impact of Neutrophil Recruitment to the Skin on the Pathology Induced byFrontiers in immunology · 2021Review
- Molecular signatures of anthroponotic cutaneous leishmaniasis in the lesions of patients infected with Leishmania tropica.Scientific reports · 2020Article
- Differential Activation of Human Keratinocytes by Leishmania Species Causing Localized or Disseminated Disease.The Journal of investigative dermatology · 2017Article
- A secondary wave of neutrophil infiltration causes necrosis and ulceration in lesions of experimental American cutaneous leishmaniasis.PloS one · 2017Article
- Chronic Gastrointestinal Nematode Infection Mutes Immune Responses to Mycobacterial Infection Distal to the Gut.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Permissive and protective roles for neutrophils in leishmaniasis.Clinical and experimental immunology · 2015Review
- Activity of synthetic chalcones in hamsters experimentally infected with Leishmania (Viannia) braziliensis.Parasitology research · 2015Article
- Proteome profiling of human cutaneous leishmaniasis lesion.The Journal of investigative dermatology · 2015Article
- Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.Cellular and molecular life sciences : CMLS · 2014Review
- Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Inhibition of caspase-8 activity promotes protective Th1- and Th2-mediated immunity to Leishmania major infection.Journal of leukocyte biology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous leishmaniasis (CL) is caused by Leishmania infection of dermal macrophages and is associated with chronic inflammation of the skin. L. aethiopica infection displays two clinical manifestations, firstly ulcerative disease, correlated to a relatively low parasite load in the skin, and secondly non-ulcerative disease in which massive parasite infiltration of the dermis occurs in the absence of ulceration of epidermis. Skin ulceration is linked to a vigorous local inflammatory response within the skin towards infected macrophages. Fas ligand (FasL) and Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expressing cells are present in dermis in ulcerative CL and both death ligands cause apoptosis of keratinocytes in the context of Leishmania infection. In the present report we show a differential expression of FasL and TRAIL in ulcerative and non-ulcerative disease caused by L. aethiopica. In vitro experiments confirmed direct FasL- and TRAIL-induced killing of human keratinocytes in the context of Leishmania-induced inflammatory microenvironment. Systemic neutralisation of FasL and TRAIL reduced ulceration in a model of murine Leishmania infection with no effect on parasitic loads or dissemination. Interestingly, FasL neutralisation reduced neutrophil infiltration into the skin during established infection, suggesting an additional proinflammatory role of FasL in addition to direct keratinocyte killing in the context of parasite-induced skin inflammation. FasL signalling resulting in recruitment of activated neutrophils into dermis may lead to destruction of the basal membrane and thus allow direct FasL mediated killing of exposed keratinocytes in vivo. Based on our results we suggest that therapeutic inhibition of FasL and TRAIL could limit skin pathology during CL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.